# Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

> **NCT00413270** · — · NO_LONGER_AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** nilotinib

## Key facts

- **NCT ID:** NCT00413270
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** 2006-12
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2011-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413270, "Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00413270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*